Author: Marie Jones

INDIA, Aug 18, 2020 – (ACN Newswire) – The COVID-19 pandemic is still being battled across the world and a lot of organizations have come to an ambiguous halt. In such uncertain times, businesses are reorienting their approach towards the new normal. Especially, for an industry like Events and Conferences, where the real essence is a large gathering of like-minded people coming together to create an experience. Adapting to the new norm, Clavent is organizing a virtual conference on 5th and 6th September 2020 called the “EMERGE 2020 MARTECH SUMMIT”. Clavent, an India based global conferences company, is hosting Emerge…

VCREDIT Holdings Limited (“VCREDIT” or the “Group”; stock code: 2003.HK), a leading independent online consumer financial service provider in China, is pleased to announce its unaudited interim results for the 6 months ended 30 June 2020 (the “Period”). During the Period, the Group’s total income was RMB1.2 billion, which was largely supported by the powerful financial technology of the Group in terms of effective risk management and enhanced asset quality, amid the outbreak of COVID-19. Based on an in-depth analysis conducted on proprietary data, the Group enhanced customer acquisition algorithms. A series of targeted risk control measures were implemented, resulting…

WPS Office Benefits from Increased Demand in Remote Working Online Games Business Achieves Excellent Performance with Operational Innovations Kingsoft Corporation Limited (“Kingsoft” or the “Company”; HKEx stock code: 03888), a leading Chinese software and Internet service company, has announced its unaudited 2020 interim results and its second quarter results for the period ended 30 June 2020. For the first half of 2020, the revenue of Kingsoft increased 41% year-on-year to RMB2,591.4 million. Revenue from the online games, and office software and services and others represented 64% and 36%, respectively, of the Company’s total revenue for the first half of 2020.…

Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to announce that the Group has been selected as a constituent of the following Hang Seng family of indices effective Monday, 7 September 2020. 1. Hang Seng Composite Index (“HSCI”) 2. Hang Seng Consumer Goods & Services Index (“HSCGSI”) 3. Hang Seng Stock Connect Hong Kong Index (“HSHKI”) 4. Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index (“HSHKMS”) 5. Hang Seng Stock Connect Hong Kong SmallCap Index (“HSHKS”) 6. Hang Seng SCHK Mainland China Companies Index (“HSSCMLC”) 7.…

C-Trade has launched a new crypto derivatives exchange platform, geared towards greater speed and efficiency for traders and offering up to 150x leverage on derivative products. C-Trade has also cut typical user withdrawal approvals time to mere minutes, inspired by personal management experience on other platforms. “I have experienced first-hand the frustrating drawbacks of derivatives trading,” said C-Trade cofounder Edmund Lee, a seasoned professional poker player and founder of a successful crypto asset management firm. “I knew we could do better than regular system overloads and endless withdrawal times, which is why we launched our constant pursuit of advanced technology…

免疫藥物公司AIM ImmunoTech(NYSE- American 交易代碼: AIM) 是一家致力於研究治療免疫疾病，病毒性疾病和多種類型癌症的療法的免疫藥物公司，今天提供了截至2020年6月30日的第二季度業務和臨床前/臨床更新。 2020年第二季度財務摘要： – 截至2020年6月30日，AIM的現金，現金等價物和有價證券為4030萬美元，而截至2019年12月31日為880萬美元。 – 截至2020年6月30日的第二季度的研發費用為146萬美元，而截至2019年6月30日的第二季度的研發費用為110萬美元。 – 截至2020年6月30日的第二季度的一般和行政支出為172萬美元，而截至2019年6月30日的第二季度的194萬美元。 公司的2020年6月30日完整財務業績包含在於2020年8月14日提交給美國證券交易委員會的10-Q表內，該表格可從www.sec.gov和公司網站上獲得。 “ AIM致力於滿足COVID-19和癌症等關鍵未滿足的醫療需求的極其重要且具有開創性的臨床前和臨床研究，這為我們在廣闊的潛在市場中提供了“多重目標”。根據這些多種表現，AIM支持這些試驗的策略是最大限度地增加直接授予臨床站點的第三方，非稀釋性資金，是我們在許多試驗中均已完成的。此外，截至2020年6月30日，我們的資產負債表上有超過4,000萬美元的現金，現金等價物和有價證券。因此，我們相信，我們非常有能力執行未來的戰略，反過來，我們預計將為股東帶來可觀的價值。” AIM首席執行官Thomas K. Equels說。 COVID-19常規更新： – 在FDA於2020年5月11日批准IND後，AIM於2020年7月6日與Roswell Park 綜合癌症中心簽署了一項臨床試驗協議，以支持Roswell Park Ampligen與乾擾素alfa-2b聯合治療的1 / 2a期臨床試驗在患有COVID-19的癌症患者中，該疾病由SARS-CoV-2引起。該試驗有望很快開始患者入組。 – AIM與日本國立傳染病研究所和 Shionogi 公司簽署了三邊材料轉移和研究協議， Shionogi 公司是總部位於日本的全球領先製藥公司，目的是測試Ampligen作為COVID-19的潛在疫苗佐劑。 Ampligen已運送到日本，之後將再進行其他運送。 – AIM目前正在與全球最大的電子煙設備製造商深圳Smoore合作，研究其創新的吸入技術在COVID-19出現第一個跡象時用於增強Ampligen深入肺部的作用。該公司認為，這種方法可能會在整個上下呼吸系統中加強針對SARS-CoV-2病毒的強大的治療性TLR3反應。 Ampligen計劃運往Smoore進行測試，等待各種中國進口法規要求解決。 – Ampligen已運送到猶他州立大學，以支持該大學的病毒研究所進行SARS-CoV-2的臨床前測試，並且測試正在進行中。 COVID-19引起的慢性疲勞樣疾病更新： – 在SARS-CoV-1動物實驗中，Ampligen已被證明是具有保護作用的強大藥物。 Ampligen在慢性疲勞綜合症(CFS)患者的2期和3期試驗中也顯示出較高的活性水平。 Ampligen在美國進行CFS試驗時，已在阿根廷獲得批准，並且是美國生產中唯一的CFS後期試驗藥物。 Ampligen還是世界上首個獲批用於嚴重CFS的藥物。 AIM正準備測試Ampligen作為SARS-CoV-2引起的慢性疲勞樣疾病的潛在療法。 AIM認為，Ampligen可能在解決這種多方面的疾病中發揮重要作用，包括潛在的感染後使人衰弱的方面。 Equels表示：“COVID-19的病毒SARS-CoV-2具有引發大量慢性疲勞樣病例的巨大風險，這與之前的SARS-CoV-1流行病相似。” “ Ampligen具有SARS-CoV-1病毒的臨床前成果的悠久歷史，為AIM帶來了希望，該藥具有潛在的預防作用，作為疫苗佐劑以及對SARS-CoV-2病毒和COVID-19的早發治療的潛力引起的慢性疲勞樣疾病。對於癌症患者而言，這種潛在療法可能尤其重要，因為他們面臨嚴重症狀或死於COVID-19的風險大大增加。” 肌炎性腦脊髓炎/慢性疲勞綜合徵更新： – AIM已獲得ANMAT的許可，可將第一批商業級小瓶Ampligen進口到阿根廷。 Ampligen業務投放的下一步包括ANMAT對產品進行最終檢查並發布測試，然後再授予最終批准以開始商業銷售。 AIM已將Ampligen交付給其在阿根廷的合作夥伴GP Pharm，是測試和ANMAT發布所必需的。一旦獲得ANMAT的最終批准，計劃在阿根廷商業領域投放Ampligen。此外，AIM繼續追求其Ampligen新藥申請或NDA，以與FDA一起治療傳統CFS。 免疫腫瘤學更新：Equels進一步指出：“鑑於我們由第三方資助，研究者資助的癌症臨床試驗的進展，我們相信AIM確實有潛力成為腫瘤學的強大力量，因為這些試驗中報告了臨床數據。 默克公司，美國國防部和美國國家癌症研究所等著名組織已向頂級國家癌症中心的世界級研究人員/腫瘤學家提供了數千萬美元的贈款，這一事實顯然支持了我對Ampligen的信心。” – Roswell Park 綜合癌症中心和 Moffitt 癌症中心均獲得了美國國防部腦轉移性乳腺癌的“突破獎”。這些分開但平行的擬議中的臨床試驗共同獲得了約1500萬美元的聯邦資金，部分重點是將Ampligen作為一種潛在的協同劑與其他幾種免疫療法結合使用，包括pembrolizumab(Keytruda)和Intron A 。 – 美國國家癌症研究所向Roswell Park 綜合癌症中心頒發了1,450萬美元的獎金，以資助針對黑素瘤，結直腸癌和卵巢癌的五項臨床試驗。這些試驗將測試結合Ampligen作為免疫調節劑的趨化因子調節，作為將“冷”腫瘤轉變為“熱”腫瘤的策略的一部分。 – 晚期復發性卵巢癌— Ampligen在晚期復發性卵巢癌中作為腹膜內治療的1/2期研究已經完成了1期的12位受試者； 1期部分建立了腹膜內安全性，足以進行更大的2期研究(見下文)。 (https://tinyurl.com/y2p9lp9l)我們正在等待結果公佈。 https://clinicaltrials.gov/ct2/show/NCT02432378 – 晚期復發性卵巢癌-基於上述研究，正在進行一項由45名受試者組成的晚期復發性卵巢癌第二階段研究，主要通過Merck 公司資助，並使用順鉑，派姆單抗和Ampligen 。入選於2019年1月開始，許多患者現已接受治療。 https://clinicaltrials.gov/ct2/show/NCT03734692 (https://tinyurl.com/y5xm5cbp) – 第四階段轉移性三陰性乳腺癌—使用趨化因子調節療法(包括Ampligen和派姆單抗)的轉移性三陰性乳腺癌的第二階段研究。所有患者均已接受治療或即將完成治療。 https://www.clinicaltrials.gov/ct2/show/NCT03599453 – 大腸癌向肝轉移的第4階段-2a期研究Ampligen作為趨化因子調節方案的組成部分對大腸癌向肝轉移的作用；在12位計劃中的患者中，大多數都接受了治療。 https://clinicaltrials.gov/ct2/show/NCT03403634 – 早期前列腺癌-2期研究調查了接受或不接受干擾素-alpha 2b(內含藥A)的阿司匹林和Ampligen與未經根治性前列腺癌患者在接受前列腺癌根治術前的三臂隨機研究中的藥物治療相比的有效性和安全性。該研究已針對45位患者進行了患者登記。 https://clinicaltrials.gov/ct2/show/NCT03899987 – 早期三重陰性乳腺癌—早期三重陰性乳腺癌患者趨化因子調節聯合新輔助化療的1期研究已獲得FDA批准；這項研究的目的是評估在與化療同時使用時，Ampligen，塞來昔布聯合或不聯合內含子A的安全性和耐受性；這種方法的目的是增加生存率。該研究正在招募中，最多可容納24位患者。 https://clinicaltrials.gov/ct2/show/NCT04081389 – Ampligen作為晚期胰腺癌藥物的研究已經完成，Erasmus M.C.的研究小組目前正在根據這項基於早期訪問批准的研究匯總最終數據。我們熱切期待這些結果的發布。 隨著國家醫療體系越來越關注COVID-19大流行，並且癌症患者尤其容易患該疾病，AIM認識到所有癌症中心(如所有醫療機構)都必須將大流行列為優先事項。因此，由於COVID-19緊急醫療情況，在癌症患者中進行正在進行的研究可能會延遲臨床試驗的註冊和隨後的報告。但是，AIM打算毫不拖延地繼續往前，我們相信所有臨床站點的團隊都渴望保持前進的勢頭。 關於AIM ImmunoTech公司 AIM ImmunoTech公司是一家免疫製藥公司，專門從事治療免疫疾病、病毒性疾病和多種癌症的療法的研究和開發。 AIM的主打產品包括阿根廷批准的藥物rintatolimod(商品名Ampligen(R)或Rintamod(R))和FDA批准的藥物Alferon N Injection(R)。根據已發表的同行評審的臨床前研究和臨床試驗結果，AIM認為Ampligen(R)可能具有廣譜抗病毒和抗癌特性。…

– Investigational first-in-class glucokinase activator, with a novel mode of action, focused on fixing the glucose sensor and restoring glucose homeostasis for Type 2 diabetes mellitus (“T2DM”) patients, with sustained efficacy in phase III clinical trial in Chinese T2DM patients. – 116 million T2DM patients in China, with an unsatisfied treatment and control rate. – Agreement further strengthens Bayer’s diabetes management leadership in China. Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. The agreement aims to provide Chinese diabetes patients with access…

MB SHINSEI Finance Limited Liability Company (Mcredit) – one of the leading consumer finance companies in Vietnam and JCB International Co, Ltd. (JCBI) – the international operations subsidiary of JCB Co., Ltd., announced the launch of the Mcredit JCB Credit Card. The new Mcredit JCB Credit Card is the very first JCB card launched in collaboration with a finance company in the Vietnamese market and offers 2 different card grades: standard and gold card. The holders of Mcredit JCB Credit Card can access the JCB acceptance network globally with about 34 million merchants and over a million ATMs in the…

World Blockchain Hackathon, a 100% community funded global organization, have announced the details of their latest hackathon on October 9 -11, 2020, a 3-day global virtual event that will attract more than 3000 participants and contributions across 50 countries. The Babylon Project aims to democratize access to global innovation with blockchain technology: its a project that aims on developing a new generation of diverse leaders in the crypto community within the next 5 years. Key Takeaways: — Community focused, protocol agnostic blockchain hackathon w/ 3000 global participants — Focusing on diversity and inclusion, with international ‘Supernode’ ambassadors — 200 international…

Mezzan will manufacture, sell and distribute to retail, restaurants and food service around the GCC Nathan’s Famous, Inc. (NASDAQ: NATH), the American tradition serving New York favorites for more than 100 years, announces today it has signed a licensing, manufacturing and distribution agreement with Mezzan Holding KSC, one of the largest manufacturers and distributors of food, beverage, FMCG and pharmaceutical products in the Gulf. This partnership further solidifies Nathan’s Famous’ commitment to the Middle East through the manufacturing and distribution of Halal Nathan’s Famous products. “We believe our partnership with Mezzan provides a wealth of advantages for the Nathan’s Famous…

Chun Can資本集團（OTC粉單交易代碼: “CNCN”）宣布，公司現已完成非洲剛果民主共和國（DRC，簡稱“剛果（金）”）一處推斷金礦儲量為3,000,000盎司的金礦收購協議，並已委派新高級管理團隊予以負責，由蘇黎世資本基金控股有限公司（Zurich Capital Funds Holdings Inc.）的Fahed Al Merhebi博士擔任董事會主席。此外，公司還任命Zoli Macanda Simbodyal女士為首席執行官，James Mufaro先生為首席運營官。 剛果（金）金礦 該金礦由本公司通過與倫敦金色廣場基金投資有限公司（Golden Square Equity Partners Limited）的協議收購。該金礦即剛果（金）Misisi金礦項目，位於剛果（金）東部，推斷金礦儲量為3,000,000盎司，品位為2.14克/噸。按今日每盎司1,946美元價格計算，黃金儲量估值將超過58億美元。 Misisi金礦項目預期為大型勘探項目，位於剛果（金）South Kivu省會Bukavu以南250公里的Misisi鎮附近。Misisi項目擁有Akyanga金礦床。該金礦床目前的推斷礦產儲量為4440萬噸，品位為2.16克/噸，按100%計算含300萬盎司，按72.15%計算含216.45萬盎司。本公司已收到由澳大利亞頂尖礦產資源諮詢公司Denny Jones Pty Ltd.出具的礦產資源報告聲明。該報告符合2012年聯合礦石儲量委員會準則（JORC準則）的要求。 私募 本公司已授權並以每股20.00美元的價格向部分合格投資者和機構投資者發行共計5,000,000股普通股（每股面值0.0001美元）的1億美元私募。所募資金將用於投資本公司已協商收購的南非、剛果（金）、加拿大、俄羅斯和澳大利亞的臨生產金礦項目。本公司預計該筆資金將於2020年12月31日午夜（太平洋標準時間）或之前完成募集。本公司保留將發行時間最多延長180天，並確認終止日期不遲於2021年7月31日的權利。 Fahed Al Merhebi博士 蘇黎世資本基金控股有限公司是一家總部位於迪拜的投資集團，Fahed Al Merhebi博士現為公司董事會主席。蘇黎世資本已收購本公司52%的普通股，成為主要控股股東。此外，Al Merhebi博士還擔任著阿拉伯非洲一體化與發展理事會（AKF-FOS AACID UN DESA CSO）副主席一職。他不僅擁有金融和國際法博士學位，還具備銀行和金融領域豐富從業經驗。在阿聯酋，Al Merhebi博士曾多次登上阿拉伯新聞，被媒體冠以“金融王子”等諸多美名，並曾當選為2016年最具影響力人物。 Zoli Macanda Simbodyal Macanda Simbodyal女士為特許會計師，擁有開普頓大學榮譽學士學位、威爾士大學金融碩士學位、南非特許會計師執照和英格蘭及威爾士特許會計師執照。她在南非和倫敦的多家公司擔任董事職務。作為財務顧問，Zoli Macanda Simbodyal女士擁有以下公司的項目管理經驗：普華永道、特許會計師和審計師協會、NM Rothschild投資銀行倫敦、紐約和南非分支機構。 James Mufaro James Mufaro先生具有津巴布韋國籍，擁有工商管理碩士學位和工程學士學位，是一位經驗豐富的採礦專家，曾在非洲擔任多個高級管理層職務。 James在加入公司之前曾在南非約翰內斯堡Samancor Chrome公司擔任首席運營總監，在此之前則為採礦主管。 Chun Can資本集團 Chun Can資本集團是一家內華達州公司，在場外上市，交易代碼為“CNCN”。公司成立於1996年8月16日（註冊編號為NV19961175609），近期完成了控制權變更，並啟動了在全球範圍內收購及運營金礦的新業務計劃。本公司現已將執行辦公室遷至阿聯酋迪拜，即公司董事會主席Fahed Al Merhebi博士辦公地點。 Chun Can資本集團 Zoli Macanda Simbodyal 首席執行官 電子郵件：zoli@beleholdings.com 來源：Chun Can資本集團

SINGAPORE, Aug 13, 2020 – (ACN Newswire) – Informa Markets announced new details for ConnecTechAsia2020 (www.connectechasia.com/broadcast-asia/), the first virtual Infocomm, Media and Technology event held in partnership with Singapore’s Infocomm Media Development Authority (IMDA), from 29 September to 1 October 2020. The event will feature some 200 exhibitors, several of which are taking part for the first time showcasing the latest 5G technologies and enterprise solutions. This group includes AT&T, SPTel, Qualcomm, ServiceNow, StarHub and Verizon. Other bellwethers will also enrich the virtual experience; they are Grass Valley, Huawei, KTSat, Roland, Sony and SingTel Satellite, to name a few. Six group pavilions bringing with…

Resolves Operational Challenges of Small and Micro Companies, Sparks New Momentum in the Post-Epidemic Era A leading payment & finance solutions provider in China, Hi Sun Technology (China) Limited (the “Company”; Stock code: 818.HK), announced the unaudited consolidated results of the Company and its subsidiaries (the “Group”) for the six months ended 30 June 2020 (the “Reporting Period”). Results Highlights 1. During the Reporting Period, COVID-19 drove a significant decrease in operation activities from small and micro companies, as well as consumer consumption of goods and services. As a result, the Group’s transaction volume of payment business fell by 22.4%,…

Cadency 9.0 launches leading financial close automation capabilities focused on greater usability, highly configurable and transparent workflows, stronger integration and expanding AI capabilities Trintech, a leading global provider of integrated Record to Report software solutions for the office of finance, today announced the release of Cadency 9.0. The latest update to Cadency’s comprehensive System of Accounting Intelligence offers new, innovative support for transaction and account reconciliation, journal entry, systems integrations, artificial intelligence and overall usability for large enterprises. “As our customers continue to focus on agility and sustainability during this time, the enhancements we have made in Cadency 9.0 deliver…

MSD collaboration to investigate QBiotics’ lead molecule tigilanol tiglate in combination with KEYTRUDA(R) (pembrolizumab) Tigilanol tiglate is a novel, small molecule being developed as an intratumoural treatment for solid tumours Melanoma the second human application for tigilanol tiglate following Company’s ongoing Phase I/II study in head and neck squamous cell carcinoma QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, is pleased to announce that it has entered into an agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA), to evaluate use of its lead molecule tigilanol tiglate, in combination with…

Turnover (excl. the effect of “two-invoice system”) up 4.6% to RMB3,557.1 Million; Profit up 11.4% to RMB1,300.5 Million; Continuous Expansion of Innovative Pipeline; Positive Progress Made in China Registration and Clinical Work; Driven by Product Competence, Promotion Capability, Efficient Management System; Operating Performance Hit a New High China Medical System Holdings Limited (“CMS”, or the “Company”, SEHK:867), together with its subsidiaries (the “Group”), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, announced its unaudited results for the 6 months ended 30 June 2020 ( the “Reporting Period”). In the first half of 2020, the…

Expects net profit increase of not less than 40% Huijing Holdings Company Limited (“Huijing Holdings” or the “Group”; Stock code: 9968), an integrated residential and commercial property developer in the PRC with a foothold in the Greater Bay Area, has today announced that it expects to record a period-on-period increase in net profit of not less than 40% for the six months ended 30 June 2020 (the “Reporting Period”). Huijing Holdings recorded a substantial increase in net profit, which was mainly attributable to the increase in the revenue of the Group due to the increase in gross floor area delivered to…

JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., and PJSCB Orient Finans are pleased to announce the start of JCB merchant acquiring operations across Uzbekistan. PJSCB Orient Finans has become the first bank in Uzbekistan to launch merchant acquiring operations for JCB, Japan’s only international payment brand. Private Joint-Stock Commercial Bank “Orient Finans” (Orient Finans Bank) was founded in 2010 and it is a full-fledged universal financial institution in the banking services market in the Republic of Uzbekistan. The reliability of the bank’s financial position is confirmed by the credit ratings of international and national rating…

Click2Match digital platform connects global exhibitors and buyers The COVID-19 pandemic has led to physical exhibitions around the world being cancelled or postponed. However, despite this impediment to economic activity, sourcing demand has continued to grow. The Hong Kong Trade Development Council (HKTDC) acted swiftly to change its strategy at the onset of the pandemic, actively developing new business channels and services. The HKTDC’s most recent online exhibition has concluded successfully, laying the foundation for a future hybrid model that combines physical and online trade fairs. In view of the pandemic, nine of the HKTDC’s planned physical exhibitions (see below)…

Record Revenue and Record Profit The global leading cordless power equipment and floor care company Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: 669, ADR symbol: TTNDY) announced an exceptional first half results for the six months ended June 30, 2020. The Group delivered sales growth of 12.8% to US$4.2 billion in reported currency or 14.0% in local currency. Gross margin improved an additional 40 basis points to 38.0%. EBIT grew 15.6% to US$363 million. Net profit and earnings per share increased 16.3% and 16.2% respectively, to US$332 million and approximately US18.14 cents per share. The strong first…